Compass Therapeutics, Inc. CMPX

Several analysts slashed their price targets on Compass Therapeutics after the FDA requested an additional trial for its cancer drug.

Compass said on Tuesday that the FDA recommended a trial showing a survival benefit before the company files a biologics license application for tovecimig in previously treated advanced biliary tract cancer.

Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index adding 0.5% and the St

Compass Therapeutics, Inc. (NASDAQ:CMPX) shares are trading lower on Tuesday as the FDA feedback raises new questions about the timing and requirements for its tovecimig program. The move is coming even as S&P 500 futures are up 0.1%, pointing to stock-specific pressure rather than a broad risk-off tape. Read Also: Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care CMPX Stock Drops After FDA Feedback On Tovecimig BLA Path Compass said the FDA recommended the company run a t

The FDA wants Compass to conduct a trial showing Tovecimig can improve overall survival in patients with previously treated, advanced biliary tract cancer.

The FDA recommended that Compass conduct a trial to demonstrate a survival benefit prior to submitting a BLA for tovecimig.Compass does not believe that a new trial is warranted prior to submitting a BLA based on the data from the Phase 2/3 COMPANION-002 study and the urgent unmet medical need for patients with BTC.Compass intends to further engage with the FDA as we continue to prepare a BLA submission for tovecimig. Compass remains confident in tovecimig based on the positive results from COMP

The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior to a potential BLA filing later this year. Tovecimig data from this study has also been selected for an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress in October.CTX-8371 (PD-1 x PD-L1 bispecific antibody) Phase 1 cohort expansions are actively enrolling patients

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (E

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the Best Small-Cap Growth Stocks to Invest In Now. ​Recently, on June 4, Citizens reiterated a Market Outperform rating on the stock with a price target of $10. The rating comes after the company presented new clinical data at the ASCO conference. ​The data was regarding the company’s […]

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main story is tovecimig, an experimental cancer treatment being developed for biliary tract cancer, which affects the bile ducts, gallbladder, or nearby digestive organs. In its May 5 first-quarter update, Compass said tovecimig had received FDA Orphan […]

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of June. Details are as follows: Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026 Time: 8:45 AM ETWebcast Link: https://cmpx.info/jefferies Goldman Sach

CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies resistant to prior immune checkpoint inhibitors.Deep and durable responses were observed in patients with triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC).CTX-8371 was generally well tolerated with no observed dose limiting toxici

Compass Therapeutics Inc. (NASDAQ:CMPX) is one of the best NASDAQ stocks under $5 to buy right now. On May 5, Compass Therapeutics reported a Q1 2026 net loss of $18.3 million, or $0.10 per share. R&D expenses rose to $13.4 million, while G&A expenses climbed 41% to $6.9 million due to stock compensation and $1.0 […]

BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of May. Details are as follows: H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ Date: Tuesday, May 19, 2026 Time: 1:30 PM ETWebcast Link: https://jour

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the 10 Best Day Trading Penny Stocks to Buy. On April 28, 2026, Canaccord lowered its price target on Compass Therapeutics, Inc. (NASDAQ:CMPX) to $7 from $13 and maintained a Buy rating. The firm said Tovecimig+paclitaxel showed improved progression-free survival versus paclitaxel monotherapy, but noted that 54% crossover […]

As recently announced, tovecimig (DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement in progression-free survival (PFS) versus paclitaxel alone as well as clear signals of a survival benefit in a Phase 2/3 study of patients with biliary tract cancer (BTC); tovecimig previously met the primary endpoint of overall response rate (ORR). Tovecimig received Orphan Drug Designation in April and the Company intends to meet with t